US20080099168A1 - Soft and absorbent tissue products - Google Patents

Soft and absorbent tissue products Download PDF

Info

Publication number
US20080099168A1
US20080099168A1 US11588076 US58807606A US2008099168A1 US 20080099168 A1 US20080099168 A1 US 20080099168A1 US 11588076 US11588076 US 11588076 US 58807606 A US58807606 A US 58807606A US 2008099168 A1 US2008099168 A1 US 2008099168A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
tissue
radical
substituted
unsubstituted
branched
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11588076
Inventor
Kou-Chang Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kimberly-Clark Worldwide Inc
Original Assignee
Kimberly-Clark Worldwide Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/02Cosmetics or similar toilet preparations characterised by special physical form
    • A61K8/0208Tissues; Wipes; Patches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/72Cosmetics or similar toilet preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84Cosmetics or similar toilet preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86Polyethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/72Cosmetics or similar toilet preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84Cosmetics or similar toilet preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/89Polysiloxanes
    • A61K8/891Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • DTEXTILES; PAPER
    • D21PAPER-MAKING; PRODUCTION OF CELLULOSE
    • D21HPULP COMPOSITIONS; PREPARATION THEREOF NOT COVERED BY SUBCLASSES D21C OR D21D; IMPREGNATING OR COATING OF PAPER; TREATMENT OF FINISHED PAPER NOT COVERED BY CLASS B31 OR SUBCLASS D21G; PAPER NOT OTHERWISE PROVIDED FOR
    • D21H21/00Non-fibrous material added to the pulp, characterised by its function, form or properties; Paper-impregnating or coating material, characterised by its function, form or properties
    • D21H21/14Non-fibrous material added to the pulp, characterised by its function, form or properties; Paper-impregnating or coating material, characterised by its function, form or properties characterised by function or properties in or on the paper
    • D21H21/22Agents rendering paper porous, absorbent or bulky
    • DTEXTILES; PAPER
    • D21PAPER-MAKING; PRODUCTION OF CELLULOSE
    • D21HPULP COMPOSITIONS; PREPARATION THEREOF NOT COVERED BY SUBCLASSES D21C OR D21D; IMPREGNATING OR COATING OF PAPER; TREATMENT OF FINISHED PAPER NOT COVERED BY CLASS B31 OR SUBCLASS D21G; PAPER NOT OTHERWISE PROVIDED FOR
    • D21H17/00Non-fibrous material added to the pulp, characterised by its constitution; Paper-impregnating material characterised by its constitution
    • D21H17/20Macromolecular organic compounds
    • D21H17/33Synthetic macromolecular compounds
    • D21H17/34Synthetic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • D21H17/36Polyalkenyalcohols; Polyalkenylethers; Polyalkenylesters
    • DTEXTILES; PAPER
    • D21PAPER-MAKING; PRODUCTION OF CELLULOSE
    • D21HPULP COMPOSITIONS; PREPARATION THEREOF NOT COVERED BY SUBCLASSES D21C OR D21D; IMPREGNATING OR COATING OF PAPER; TREATMENT OF FINISHED PAPER NOT COVERED BY CLASS B31 OR SUBCLASS D21G; PAPER NOT OTHERWISE PROVIDED FOR
    • D21H17/00Non-fibrous material added to the pulp, characterised by its constitution; Paper-impregnating material characterised by its constitution
    • D21H17/20Macromolecular organic compounds
    • D21H17/33Synthetic macromolecular compounds
    • D21H17/46Synthetic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • D21H17/59Synthetic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon
    • DTEXTILES; PAPER
    • D21PAPER-MAKING; PRODUCTION OF CELLULOSE
    • D21HPULP COMPOSITIONS; PREPARATION THEREOF NOT COVERED BY SUBCLASSES D21C OR D21D; IMPREGNATING OR COATING OF PAPER; TREATMENT OF FINISHED PAPER NOT COVERED BY CLASS B31 OR SUBCLASS D21G; PAPER NOT OTHERWISE PROVIDED FOR
    • D21H27/00Special paper not otherwise provided for, e.g. made by multi-step processes
    • D21H27/002Tissue paper; Absorbent paper

Abstract

Softening compositions for tissues, particularly facial tissues, include a combination of polysiloxanes and one or both of a polyalkylene oxide and a fatty alkyl derivative. The softening compositions can contain from about 30 to about 75 weight percent polysiloxane, from about 0 to about 60 weight percent polyalkylene oxide and from about 0 to about 60 weight percent fatty alkyl derivative, wherein the combined amount of the polyalkylene oxide and the fatty alkyl derivative is about 25 weight percent or greater. The resulting tissues have good softness and wettability.

Description

    BACKGROUND OF THE INVENTION
  • The use of various polysiloxanes to soften tissue products, such as facial and bath tissue, is well known in the tissue industry. However, while polysiloxanes are effective in providing a smooth surface feel, they are generally hydrophobic and retard wettability. In addition, polysiloxanes can be expensive. Therefore there is a need for lower cost polysiloxane compositions which provide the desired level of softness without reducing the wettability of the tissue to unacceptable levels.
  • SUMMARY OF THE INVENTION
  • It has now been discovered that certain blends of components can provide tissues with the desired balance of softness and wettability at a reduced cost compared to current polysiloxane softness compositions. More specifically, it has been found that polysiloxanes can be combined with one or more polyalkylene oxides and/or one or more fatty alkyl derivatives in the proper ratios, particularly when the polyalkylene oxide(s) and/or the fatty alkyl derivative(s) is(are) solid at room temperature, to provide improved softness compared to the polysiloxane alone, as well as good wettability for tissue products, particularly facial tissues.
  • Hence, in one aspect, the invention resides in a softening composition which comprises, on a solids basis, from about 30 to about 75 weight percent of one or more polysiloxanes, from about 0 to about 60 weight percent of one or more polyalkylene oxides and from about 0 to about 60 weight percent of one or more fatty alkyl derivatives, wherein the combined amount of the polyalkylene oxide(s) and the fatty alkyl derivative(s) is about 25 weight percent or greater.
  • In another aspect the invention resides in a tissue sheet having a topically-applied softening composition which comprises, on a solids basis, from about 30 to about 75 weight percent of one or more polysiloxanes, from about 0 to about 60 weight percent of one or more polyalkylene oxides and from about 0 to about 60 weight percent of one or more fatty alkyl derivatives, wherein the combined amount of the polyalkylene oxide(s) and the fatty alkyl derivative(s) is about 25 weight percent or greater.
  • The softening composition can topically applied onto one or both of the outer tissue product surfaces, such as by printing or spraying, or by any other manner known in the tissue making art. Topical addition tends to concentrate the softening composition on the surface(s) of the tissue product where its softening characteristics are most readily apparent to the consumer. The add-on amount can be from about 0.5 to about 10 weight percent, more specifically from about 0.5 to about 5 weight percent, and still more specifically from about 1 to about 3 weight percent.
  • Polysiloxanes useful for purposes of this invention can have one or more pendant functional groups such as amine, quaternium, aldehyde, epoxy, hydroxy, alkoxyl, polyether and carboxylic acid and its derivatives, such as amides and esters. Suitable polysiloxanes can have the following general structure:
  • Figure US20080099168A1-20080501-C00001
  • wherein:
    “m” is from 10 to 100,000;
    “n” is from 1 to 10,000;
    “p” is from 0 to 1,000;
  • “A” and “B” are independently a hydroxyl, C1 to C20 or R2; R1, R2 and R3 are distributed in random or block fashion; R1 is a C1 to C8 radical, which can be straight chain, branched or cyclic;
  • R2 is a C1 to C8 radical, which can be straight chain, branched or cyclic, or of the structure:
  • Figure US20080099168A1-20080501-C00002
  • wherein
      • R4 and R5 are independently a C2 to C8 alkylene diradical, which can be straight chain or branched, substituted, or unsubstituted;
      • X is an oxygen or N—R8;
      • R6, R7 and R8 are independently hydrogen, a substituted or unsubstituted C1 or C2, a substituted or unsubstituted straight chain or branched or cyclic C3 to C20 alkyl radical, or an acyl radical, such as an acetyl radical; and
      • “s” is 0 or 1;
        R3 is of the structure: R9—Y—[C2H4O]r—[C3H6O]q—R10
      • wherein
      • Y is an oxygen or N—R11;
      • R9 is a C2 to C8 alkylene diradical, which can be straight chain or branched, substituted or unsubstituted;
      • R10 and R11 are independently hydrogen, a substituted or unsubstituted C1 or C2, a substituted or unsubstituted, straight chain or branched or cyclic C3 to C20 alkyl radical;
      • “r” is from 1 to 100,000; and
      • “q” is from 0 to 100,000.
    When R2=R1, “A” and “B” can also be a nitrogen quaternium.
  • Examples of suitable commercially available polysiloxanes include AF-2340, AF-2130, HAF-1130, EAF-3000, EAF-340, EAF-15, AF-2740, WR-1100, WR-1300 and Wetsoft CTW from Kelmar/Wacker; DC-8822, DC-8566, DC-8211, DC-SF8417, DC-2-8630, DC-NSF, DC-8413, DC-SSF, DC-8166 from Dow Corning; SF-69, SF-99 SF-1023 from GE Silicones and Tegopren 6924, Tegopren 7990, Tego IS4111 from Goldschmidt/Degussa.
  • The amount of the polysiloxane in the softening composition, on a solids basis, can be from about 30 to about 75 weight percent, more specifically from 30 to about 70 weight percent, more specifically from about 40 to about 70 weight percent, and still more specifically from about 50 to about 70 weight percent.
  • Polyalkylene oxides suitable for purposes of this invention can have the following general structure:

  • R12—[C2H4O}i—[C3H6O]j—[CtH2tO]v—R13
  • wherein:
  • R12 and R13 are independently a hydrogen, a substituted or unsubstituted C1 to C6 alkyl radical, a straight chain or branched C1 to C6 alkyl radical, or a cyclic C1 to C6 alkyl radical;
  • “i”, “j” and “v” are independently from 0 to 100,000, with the oxide moieties are distributed along the polymer backbone randomly or as blocks;
    “i+j+v” is equal to or greater than 10; and
    “t” is from 4 to 10.
  • The polyalkylene oxide can be in a liquid or solid state at room temperature. However, a polyalkylene oxide which is solid at room temperature is preferred. Examples of suitable commercially available polyalkylene oxides are Carbowax PEG 600, Carbowax PEG 1450 and Carbowax PEG 8000 from Dow Chemical.
  • The amount of the polyalkylene oxide in the softening composition, on a solids basis, can be from 0 to about 60 weight percent, more specifically from about 1 to about 60 weight percent, more specifically from about 10 to about 60 weight percent, more specifically from about 20 to about 60 weight percent, more specifically from about 30 to about 60 weight percent, and still more specifically from about 30 to about 50 weight percent.
  • Fatty alkyl derivatives suitable for purposes of this invention can have the following general structure:

  • R14-G
  • wherein:
  • R14 is a C8 to C40 alkyl radical, which can be substituted or unsubstituted, primary, secondary or tertiary; straight chain, branched or cyclic; and “G” is hydroxy, amine, sulfonate, sulfate, phosphate, acid or acid derivative, or -Q-[C2H4O]i—[C3H6O]j—[CtH2tO]v—R13 radical;
  • wherein
      • “Q” is an oxygen radical, an NH radical or N—[C2H4O}i—[C3H6O]j—[CtH2tO]v—R13 radical;
      • R13 is a hydrogen, a substituted or unsubstituted C1 to C6 alkyl radical, a straight chain or branched C1 to C6 alkyl radical, or a cyclic C1 to C6 alkyl radical;
      • “i”, “j” and “v” are independently from 0 to 100,000, where the oxide moieties are distributed along the polymer backbone randomly or as blocks;
      • “i+j+v” is equal to or greater than 10; and
      • “t” is from 4 to 10.
  • The fatty alkyl derivatives can be in liquid or solid state at room temperature. However, a fatty alkyl derivative which is a solid at room temperature is preferred. Examples of commercially available suitable fatty alkyl derivatives are glycerol stearate, glycerol dilaurate, sorbitan monopalmitate, sorbitan tristearate, sorbitan sesquioleate polyoxyethylene sorbitan palmitate, 9-EO ethoxylated tridecylalcohol, Ceteth-10, Ceteth-12 (12-EO ethoxylated cetyl alcohol) and Ceteth-20. More particularly, suitable commercially available fatty alkyl derivatives include Pluraface A-38, Macol CSA 20 and Macol LA 12 from BASF; Armeen 16D, Armeen 18D, Armeen HTD, Armeen 2C, Armeen M2HT, Armeen 380, Ethomeen 18/15 Amid 0, Witconate 90, Witconate AOK, and Witcolate C from Akzo Nobel.
  • The amount of the fatty alkyl derivative in the softening composition, on a solids basis, can be from 0 to 60 weight percent, more specifically from about 1 to about 60 weight percent, more specifically from about 1 to about 50 weight percent, more specifically from about 10 to about 50 weight percent, more specifically from about 20 to about 50 weight percent, and still more specifically from about 20 to about 40 weight percent.
  • In the interests of brevity and conciseness, any ranges of values set forth in this specification are to be construed as written description support for claims reciting any sub-ranges having endpoints which are whole number values within the specified range in question. By way of a hypothetical illustrative example, a disclosure in this specification of a range of from 1 to 5 shall be considered to support claims to any of the following sub-ranges: 1-4; 1-3; 1-2; 2-5; 2-4; 2-3; 3-5; 3-4; and 4-5.
  • EXAMPLES
  • Three-ply, wet-pressed, creped facial tissue products were made with different softening compositions of this invention as described below and tested for softness and wettability. In general, the tissue base sheets were produced using a conventional wet-pressed tissue making process well known in the art. More particularly, an aqueous suspension of papermaking fibers was issued from a layered headbox onto a forming fabric. The furnish consisted of 70 weight percent hardwood (eucalyptus) fibers and 30 weight percent softwood fibers. A vacuum box beneath forming fabric was adapted to remove water from the fiber furnish to assist in forming a web. The newly formed web was transferred to a felt with aid of a pick up roll. While supported by the felt, the tissue web was lightly pressed onto the surface of a Yankee dryer using a press roll. The dried web was creped from the surface of the Yankee dryer and the resulting single-ply tissue base sheet was wound onto a parent roll. Thereafter, the base sheets from three like parent rolls were unwound and converted into a three-ply basesheet for subsequent application of the various softening compositions. The finished basis weight of the three-ply base sheet was about 22.7 pounds per 2880 square feet.
  • The softening composition was simultaneously applied to both surfaces of the three-ply basesheet by rotogravure printing. The gravure rolls were electronically engraved, chrome over copper rolls supplied by Southern Graphics Systems, located at Louisville, Ky. The rolls had a line screen of 360 cells per lineal inch and a volume of 1.5 Billion Cubic Microns (BCM) per square inch of roll surface. Typical cell dimensions for this roll were 65 microns in length, 110 microns in width, and 13 microns in depth. The rubber backing offset applicator rolls were a 75 Shore A durometer cast polyurethane supplied by American Roller Company, located at Union Grove, Wis. The process was set up to a condition having 0.375 inch interference between the gravure rolls and the rubber backing rolls and 0.003 inch clearance between the facing rubber backing rolls. The simultaneous offset/offset gravure printer was run at a speed of 2000 feet per minute. This process yielded a solids add-on level of about 1.0 weight percent based on the dry weight of the finished tissue product. (0.5 dry weight percent on each side of the product.
  • After the tissue products were made, they were tested for geometric mean tensile strength, wettability and softness.
  • As used herein, the “geometric mean tensile strength” (GMT) is the square root of the product of the dry machine direction tensile strength multiplied by the dry cross-machine direction tensile strength and is expressed as grams per 3 inches of sample width. The machine direction tensile strength is the peak load per 3 inches of sample width when a sample is pulled to rupture in the machine direction. Similarly, the cross-machine direction (CD) tensile strength is the peak load per 3 inches of sample width when a sample is pulled to rupture in the cross-machine direction. More specifically, samples for tensile strength testing are prepared by cutting a 3 inches (76.2 mm) wide by inches (127 mm) long strip in either the machine direction (MD) or cross-machine direction (CD) orientation using a JDC Precision Sample Cutter (Thwing-Albert Instrument Company, Philadelphia, Pa., Model No. JDC 3-10, Serial No. 37333). The instrument used for measuring tensile strengths is an MTS Systems Sintech 11S, Serial No. 6233. The data acquisition software is MTS TestWorks® for Windows Ver. 3.10 (MTS Systems Corp., Research Triangle Park, N.C.). The load cell is selected from either a 50 Newton or 100 Newton maximum, depending on the strength of the sample being tested, such that the majority of peak load values fall between 10-90% of the load cell's full scale value. The gauge length between jaws is 4+/−0.04 inches (101.6+/−1 mm). The jaws are operated using pneumatic-action and are rubber coated. The minimum grip face width is 3 inches (76.2 mm), and the approximate height of a jaw is 0.5 inches (12.7 mm). The crosshead speed is 10+/−0.4 inches/min (254+/−1 mm/min), and the break sensitivity is set at 65%. The sample is placed in the jaws of the instrument, centered both vertically and horizontally. The test is then started and ends when the specimen breaks. The peak load is recorded as either the “MD tensile strength” or the “CD tensile strength” of the specimen depending on direction of the sample being tested. At least six (6) representative specimens are tested for each product or sheet, taken “as is”, and the arithmetic average of all individual specimen tests is either the MD or CD tensile strength for the product or sheet.
  • Wettability of the tissue products is determined by the “Wet Out Time”, which is related to absorbency, and is the time it takes for a prepared sample to completely wet out when placed in water. More specifically, the Wet Out Time is determined by cutting 20 product sheets of the tissue sample into 2.5 inch squares. The number of product sheets used in the test is independent of the number of plies per sheet of product. (For a 3-ply product were are 60 plies in each pad.) The 20 square sheets are stacked together and stapled at each corner to form a pad. The pad is held close to the surface of a constant temperature distilled water bath (23±2° C.), which is the appropriate size and depth to ensure the saturated specimen dose not contact the bottom of the container and the top surface of the water at the same time, and dropped flat onto the water surface, staple points down. The time taken for the pad to become completely saturated, measured in seconds, is the Wet out Time for the sample and represents the absorbent rate of the tissue. Increases in the Wet Out Time represent a decrease in the absorbent rate.
  • Softness of the tissue products was determined by a trained in-hand ranking panel, which provides a basic assessment of the softness and stiffness characteristics of a tissue product. The ranking panel is trained to provide holistic assessments as close as possible to those that a typical consumer might provide. In carrying out the test, two different assessments are made: Softness and Softness-on-Face. The Softness test involves evaluating the velvety, silky or fuzzy feel of the tissue sample when rubbed between the thumb and fingers. The Softness-on-Face test involves rubbing the tissue sample against the face, including the area between the nose and lips. Rank data generated for each sample code by the panel are analyzed using a proportional hazards regression model. This model assumes computationally that the panelist proceeds through the ranking procedure from most of the attribute being assessed to least of the attribute. The softness test results are presented in the tables below as log odds values. The log odds are the natural logarithm of the risk ratios that are estimated for each code from the proportional hazards regression model. Larger log odds indicate the attribute of interest is perceived with greater intensity.
  • Example 1
  • Two tissue softening compositions were prepared and supplied by the Kelmar Division of Wacker Chemical Corporation, Duncan, S.C. The relevant chemical components of the formulations are set forth in Table 1. Tissue samples were prepared as described above by gravure coating the two formulations on a three-ply, wet-pressed, creped facial tissue basesheet. A total add-on of 1 weight percent (0.5 weight percent on each side) was evenly coated on both sides of the basesheet. The treated basesheets were then converted into folded facial tissue products. (The percentage of each component, on a solids basis, is in parentheses).
  • TABLE 1
    Water and
    other
    12-EO 9-EO formulation
    Ethoxylated Ethoxylated aids
    Polysiloxane Cetyl tridecyl balance to
    Formulation AF-23 alcohol alcohol 100%
    1 (Control)   30% (83%) 0% (0%) 6% (17%)
    2 (Invention) 22.5% (67%)  5% (15%) 6% (18%)
  • The GMT and Wet Out Time of the facial tissue products were measured and the Softness and Softness-on-Face of the tissue products were evaluated. The results are set forth in Table 2 below.
  • TABLE 2
    Soft on
    Formulation GMT WOT Face Softness
    1 (Control) 933 34.5 0.2308 −0.0646
    2 (Invention) 929 25.6 0.9738 0.3842
  • The results illustrate that at similar physical strength (GMT), the tissue product treated with the softening chemical composition of this invention (Formulation 2) has a shorter Wet Out Time (or better wettability) and was softer in general and softer on the face when compared with the tissue product treated with the control (Formulation 1) (In Formulation 1, the combined amount of the polyalkylene oxide(s) and the fatty alkyl derivative(s) is less than 25 weight percent.)
  • Example 2
  • Softening compositions designated as Formulations 3-8 in Table 3 were prepared, applied to tissue samples and tested as described in Example 1. (The percentage of each component, on a solids basis, is in parentheses). The test results are set forth in Table 4.
  • TABLE 3
    Water and
    other
    Polyethylene 9-EO formulation
    Polysiloxane oxide Ethoxylated aids balance
    Formulation (AF-23) (PEG 1450) tridecylalcohol to 100%
    3 (Control) 30% (83%) 0% (0%) 6% (17%)
    4 (Invention) 21% (58%)  9% (25%) 6% (17%)
    5 (Invention) 18% (50) 12% (33%) 6% (17%)
    6 (Invention) 15% (42%) 15% (42%) 6% (17%)
    7 (Invention) 12% (33%) 18% (50%) 6% (17%)
    8 (Invention)  9% (25%) 21% (58%) 6% (17%)
  • TABLE 4
    Formulation GMT WOT Soft-on-Face Softness
    3 (Control) 964 32.2 0.5053 −0.0344
    4 (Invention) 975 25.6 0.7572 0.1405
    5 (Invention) 980 30.3 0.9222 −0.1781
    6 (Invention) 979 30.9 0.8172 0.1056
    7 (Invention) 971 22.9 0 0
    8 (Invention) 1043 16.7 0.3191 −1.0158
  • The results shown in Table 4 illustrate that at similar physical strength (GMT), tissue products treated with the softening compositions of this invention, such as the tissue product treated with Formulation 4, has a shorter Wet Out Time (better wettability) and was softer in general and softer on the face when compared with the tissue product treated with the control (Formulation 3).
  • It will be appreciated that the foregoing description and examples, given for purposes of illustration, are not to be construed as limiting the scope of this invention, which is defined by the following claims and all equivalents thereto.

Claims (28)

  1. 1. A tissue sheet having from about 0.5 to about 10 dry weight percent of a topically-applied softening composition which comprises, on a solids basis, from about 30 to about 75 weight percent of one or more polysiloxanes, from about 0 to about 60 weight percent of one or more polyalkylene oxides and from about 0 to about 60 weight percent of one or more fatty alkyl derivatives, wherein the combined amount of the polyalkylene oxide(s) and the fatty alkyl derivative(s) is about 25 weight percent or greater.
  2. 2. The tissue sheet of claim 1 wherein one or more of the polysiloxanes has the following general structure:
    Figure US20080099168A1-20080501-C00003
    wherein:
    “m” is from 10 to 100,000;
    “n” is from 1 to 10,000;
    “p” is from 0 to 1,000;
    “A” and “B” are independently a hydroxyl, C1 to C20 or R2;
    R1, R2 and R3 are distributed in random or block fashion;
    R1 is a C1 to C8 radical, which can be straight chain, branched or cyclic;
    R2 is a C1 to C8 radical, which can be straight chain, branched or cyclic, or of the structure:
    Figure US20080099168A1-20080501-C00004
    wherein
    R4 and R5 are independently a C2 to C8 alkylene diradical, which can be straight chain or branched, substituted, or unsubstituted;
    X is an oxygen or N—R8;
    R6, R7 and R8 are independently hydrogen, a substituted or unsubstituted C1 or C2, a substituted or unsubstituted straight chain or branched or cyclic C3 to C20 alkyl radical, or an acyl radical, such as an acetyl radical; and
    “s” is 0 or 1;
    R3 is of the structure: R9—Y—[C2H4O]r—C3H6O]q—R10
    wherein
    Y is an oxygen or N—R11;
    R9 is a C2 to C8 alkylene diradical, which can be straight chain or branched, substituted or unsubstituted;
    R10 and R11, are independently hydrogen, a substituted or unsubstituted C1 or C2, a substituted or unsubstituted, straight chain or branched or cyclic C3 to C20 alkyl radical;
    “r” is from 1 to 100,000; and
    “q” is from 0 to 100,000.
  3. 3. The tissue of claim 2 wherein R2 is an alkylene substituted with a di-amine or a mono-amine.
  4. 4. The tissue of claim 2 wherein R2=R1 and “A” and “B” are a nitrogen quaternium.
  5. 5. The tissue of claim 1 wherein the polyalkylene oxide has the following general structure:

    R12—[C2H4O]i—[C3H6O]j—[CtH2tO]v—R13
    wherein:
    R12 and R13 are independently a hydrogen, a substituted or unsubstituted C1 to C6 alkyl radical, a straight chain or branched C1 to C6 alkyl radical, or a cyclic C1 to C6 alkyl radical;
    “i”, “j” and “v” are independently from 0 to 100,000, with the oxide moieties are distributed along the polymer backbone randomly or as blocks;
    “i+j+v” is equal to or greater than 10; and
    “t” is from 4 to 10.
  6. 6. The tissue of claim 4 wherein the polyalkylene oxide is a polyethylene oxide or a polyethylene glycol.
  7. 7. The tissue of claim 6 wherein the polyethylene oxide or polyethylene glycol has a molecular weight greater than 600.
  8. 8. The tissue of claim 4 wherein the polyalkylene oxide is polyethylene glycol.
  9. 9. The tissue of claim 1 wherein the polyalkylene oxide is a solid at room temperature.
  10. 10. The tissue of claim 1 wherein the fatty alkyl derivative has the following general structure:

    R14-G
    wherein:
    R14 is a C8 to C40 alkyl radical, which can be substituted or unsubstituted, primary, secondary or tertiary; straight chain, branched or cyclic; and
    “G” is hydroxy, amine, sulfonate, sulfate, phosphate, acid or acid derivative, or -Q-[C2H4O]i—[C3H6O]j—[CtH2tO]v—R13 radical;
    wherein
    “Q” is an oxygen radical, an NH radical or N—[C2H4O}i—[C3H6O]j—[CtH2tO]v—R13 radical;
    R13 is a hydrogen, a substituted or unsubstituted C1 to C6 alkyl radical, a straight chain or branched C1 to C6 alkyl radical, or a cyclic C1 to C6 alkyl radical;
    “i”, “j” and “v” are independently from 0 to 100,000, where the oxide moieties are distributed along the polymer backbone randomly or as blocks;
    “i+j+v” is equal to or greater than 10; and
    “t” is from 4 to 10.
  11. 11. The tissue of claim 1 wherein the fatty alkyl derivative is an ethoxylated alcohol or a mixtures of ethoxylated alcohols.
  12. 12. The tissue of claim 11 wherein an ethoxylated alcohol has a carbon chain length of 12 or greater.
  13. 13. The tissue of claim 11 wherein the fatty alkyl derivative is an ethoxylated tridecyl alcohol.
  14. 14. The tissue of claim 11 wherein the fatty alkyl derivative is an ethoxylated cetyl alcohol.
  15. 15. The tissue of claim 10 wherein the fatty alkyl derivative is a solid at room temperature.
  16. 16. The tissue of claim 1 wherein the polysiloxane is an amino-derivatized polysiloxane and the fatty alkyl derivative is an alkylenoxylated alcohol.
  17. 17. The tissue of claim 1 wherein the polysiloxane is an amino-derivatized polysiloxane and the fatty alkyl derivative is an alkylenoxylated amine.
  18. 18. The tissue of claim 1 wherein the tissue softening composition comprises about 70 weight of an amino-polysiloxane and about 30 weight percent of an ethoxylated alcohol or a mixture of ethoxylated alcohols.
  19. 19. The tissue of claim 18 wherein the ethoxylated alcohols are in solid form at room temperature.
  20. 20. The tissue of claim 1 wherein the tissue softening composition comprises from about 50 to about 70 weight percent of an amino-polysiloxane and from about 30 to about 50 weight percent polyethylene glycol.
  21. 21. The tissue of claim 20 wherein the polyethylene glycol is a solid at room temperature.
  22. 22. The tissue of claim 1 wherein the tissue softening composition comprise from about 50 to about 70 weight percent of an amino-polysiloxane and from about 30 to about 50 weight percent of a mixture of at least one polyethylene glycol and at least one fatty alkyl derivative
  23. 23. The tissue of claim 22 wherein the polyethylene glycol and fatty alkyl derivative are in solid form at room temperature.
  24. 24. A softening composition which comprises, on a solids basis, from about 30 to about 75 weight percent of one or more polysiloxanes, from about 0 to about 60 weight percent of one or more polyalkylene oxides and from about 0 to about 60 weight percent of one or more fatty alkyl derivatives, wherein the combined amount of the polyalkylene oxide(s) and the fatty alkyl derivative(s) is about 25 weight percent or greater.
  25. 25. The composition of claim 24 wherein one or more of the polysiloxanes has the following general structure:
    Figure US20080099168A1-20080501-C00005
    wherein:
    “m” is from 10 to 100,000;
    “n” is from 1 to 10,000;
    “p” is from 0 to 1,000;
    “A” and “B” are independently a hydroxyl, C1 to C20 or R2;
    R1, R2 and R3 are distributed in random or block fashion;
    R1 is a C1 to C8 radical, which can be straight chain, branched or cyclic;
    R2 is a C1 to C8 radical, which can be straight chain, branched or cyclic, or of the structure:
    Figure US20080099168A1-20080501-C00006
    wherein
    R4 and R5 are independently a C2 to C8 alkylene diradical, which can be straight chain or branched, substituted, or unsubstituted;
    X is an oxygen or N—R8;
    R6, R7 and R8 are independently hydrogen, a substituted or unsubstituted C1 or C2, a substituted or unsubstituted straight chain or branched or cyclic C3 to C20 alkyl radical, or an acyl radical, such as an acetyl radical; and
    “s” is 0 or 1;
    R3 is of the structure: R9—Y—[C2H4O]r—[C3H6O]q—R10
    wherein
    Y is an oxygen or N—R1;
    R9 is a C2 to C8 alkylene diradical, which can be straight chain or branched, substituted or unsubstituted;
    R10 and R11, are independently hydrogen, a substituted or unsubstituted C1 or C2, a substituted or unsubstituted, straight chain or branched or cyclic C3 to C20 alkyl radical;
    “r” is from 1 to 100,000; and
    “q” is from 0 to 100,000.
  26. 26. The composition of claim 25 wherein R2=R1 and “A” and “B” are a nitrogen quaternium.
  27. 27. The composition of claim 24 wherein the polyalkylene oxide has the following general structure:

    R12—[C2H4O}i—[C3H6O]j—[CtH2tO]v—R13
    wherein:
    R12 and R13 are independently a hydrogen, a substituted or unsubstituted C1 to C6 alkyl radical, a straight chain or branched C1 to C6 alkyl radical, or a cyclic C1 to C6 alkyl radical;
    “i”, “j” and “v” are independently from 0 to 100,000, with the oxide moieties are distributed along the polymer backbone randomly or as blocks;
    “i+j+v” is equal to or greater than 10; and
    “t” is from 4 to 10.
  28. 28. The composition of claim 24 wherein the fatty alkyl derivative has the following general structure:

    R14-G
    wherein:
    R14 is a C8 to C40 alkyl radical, which can be substituted or unsubstituted, primary, secondary or tertiary; straight chain, branched or cyclic; and
    “G” is hydroxy, amine, sulfonate, sulfate, phosphate, acid or acid derivative, or -Q-[C2H4O]i—[C3H6O]j—[CtH2tO]v—R13 radical;
    wherein
    “Q” is an oxygen radical, an NH radical or N—[C2H4O}i—[C3H6O]j—[CtH2tO]v—R13 radical;
    R13 is a hydrogen, a substituted or unsubstituted C1 to C6 alkyl radical, a straight chain or branched C1 to C6 alkyl radical, or a cyclic C1 to C6 alkyl radical;
    “i”, “j” and “v” are independently from 0 to 100,000, where the oxide moieties are distributed along the polymer backbone randomly or as blocks;
    “i+j+v” is equal to or greater than 10; and
    “t” is from 4 to 10.
US11588076 2006-10-26 2006-10-26 Soft and absorbent tissue products Abandoned US20080099168A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11588076 US20080099168A1 (en) 2006-10-26 2006-10-26 Soft and absorbent tissue products

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US11588076 US20080099168A1 (en) 2006-10-26 2006-10-26 Soft and absorbent tissue products
PCT/IB2007/053070 WO2008050244A3 (en) 2006-10-26 2007-08-03 Soft and absorbent tissue products
KR20097008481A KR20090082372A (en) 2006-10-26 2007-08-03 Soft and absorbent tissue products
AU2007310471A AU2007310471A1 (en) 2006-10-26 2007-08-03 Soft and absorbent tissue products
EP20070825986 EP2051686B1 (en) 2006-10-26 2007-08-03 Soft and absorbent tissue products
JP2009533992A JP2010507435A (en) 2006-10-26 2007-08-03 Flexible and absorbent certain tissue products
CA 2665971 CA2665971A1 (en) 2006-10-26 2007-08-03 Soft and absorbent tissue products
MX2009004313A MX2009004313A (en) 2006-10-26 2007-08-03 Soft and absorbent tissue products.
US12630162 US20100143584A1 (en) 2006-10-26 2009-12-03 Method of Making Soft and Absorbent Tissue Products

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12630162 Continuation US20100143584A1 (en) 2006-10-26 2009-12-03 Method of Making Soft and Absorbent Tissue Products

Publications (1)

Publication Number Publication Date
US20080099168A1 true true US20080099168A1 (en) 2008-05-01

Family

ID=39232970

Family Applications (2)

Application Number Title Priority Date Filing Date
US11588076 Abandoned US20080099168A1 (en) 2006-10-26 2006-10-26 Soft and absorbent tissue products
US12630162 Abandoned US20100143584A1 (en) 2006-10-26 2009-12-03 Method of Making Soft and Absorbent Tissue Products

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12630162 Abandoned US20100143584A1 (en) 2006-10-26 2009-12-03 Method of Making Soft and Absorbent Tissue Products

Country Status (6)

Country Link
US (2) US20080099168A1 (en)
EP (1) EP2051686B1 (en)
JP (1) JP2010507435A (en)
KR (1) KR20090082372A (en)
CA (1) CA2665971A1 (en)
WO (1) WO2008050244A3 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080230196A1 (en) * 2007-03-22 2008-09-25 Kou-Chang Liu Softening compositions for treating tissues which retain high rate of absorbency
US20080230195A1 (en) * 2007-03-22 2008-09-25 Frederick John Lang Tissue products containing non-fibrous polymeric surface structures and a topically-applied softening composition

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6198221B2 (en) * 2013-07-18 2017-09-20 河野製紙株式会社 Surface coated crepe paper and a manufacturing method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196499A (en) * 1991-03-25 1993-03-23 Siltech, Inc. Terminal silicone ester quaternary compounds
US5538595A (en) * 1995-05-17 1996-07-23 The Proctor & Gamble Company Chemically softened tissue paper products containing a ploysiloxane and an ester-functional ammonium compound
US5580566A (en) * 1992-06-26 1996-12-03 Kimberly-Clark Corporation Preserved polysiloxane emulsions for treating tissues
US6949168B2 (en) * 2002-11-27 2005-09-27 Kimberly-Clark Worldwide, Inc. Soft paper product including beneficial agents
US20060130989A1 (en) * 2004-12-22 2006-06-22 Kimberly-Clark Worldwide, Inc. Tissue products treated with a polysiloxane containing softening composition that are wettable and have a lotiony-soft handfeel

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5017365A (en) * 1988-05-09 1991-05-21 Solarcare Technologies Corporation Sunscreen composition and applicator system
US5059282A (en) * 1988-06-14 1991-10-22 The Procter & Gamble Company Soft tissue paper
US5575891A (en) * 1995-01-31 1996-11-19 The Procter & Gamble Company Soft tissue paper containing an oil and a polyhydroxy compound
US6017418A (en) * 1996-12-23 2000-01-25 Fort James Corporation Hydrophilic, humectant, soft, pliable, absorbent paper and method for its manufacture
US6284234B1 (en) * 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
US6605666B1 (en) * 2000-07-27 2003-08-12 3M Innovative Properties Company Polyurethane film-forming dispersions in alcohol-water system
US6576248B1 (en) * 2000-09-11 2003-06-10 Avon Products, Inc. Pigmented vitamin C composition
US7396593B2 (en) * 2003-05-19 2008-07-08 Kimberly-Clark Worldwide, Inc. Single ply tissue products surface treated with a softening agent
US20050136097A1 (en) * 2003-12-19 2005-06-23 Kimberly-Clark Worldwide, Inc. Soft paper-based products

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196499A (en) * 1991-03-25 1993-03-23 Siltech, Inc. Terminal silicone ester quaternary compounds
US5580566A (en) * 1992-06-26 1996-12-03 Kimberly-Clark Corporation Preserved polysiloxane emulsions for treating tissues
US5538595A (en) * 1995-05-17 1996-07-23 The Proctor & Gamble Company Chemically softened tissue paper products containing a ploysiloxane and an ester-functional ammonium compound
US6949168B2 (en) * 2002-11-27 2005-09-27 Kimberly-Clark Worldwide, Inc. Soft paper product including beneficial agents
US20060130989A1 (en) * 2004-12-22 2006-06-22 Kimberly-Clark Worldwide, Inc. Tissue products treated with a polysiloxane containing softening composition that are wettable and have a lotiony-soft handfeel

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080230196A1 (en) * 2007-03-22 2008-09-25 Kou-Chang Liu Softening compositions for treating tissues which retain high rate of absorbency
US20080230195A1 (en) * 2007-03-22 2008-09-25 Frederick John Lang Tissue products containing non-fibrous polymeric surface structures and a topically-applied softening composition

Also Published As

Publication number Publication date Type
WO2008050244A3 (en) 2009-05-28 application
US20100143584A1 (en) 2010-06-10 application
CA2665971A1 (en) 2008-05-02 application
JP2010507435A (en) 2010-03-11 application
WO2008050244A2 (en) 2008-05-02 application
KR20090082372A (en) 2009-07-30 application
EP2051686A2 (en) 2009-04-29 application
EP2051686B1 (en) 2011-05-18 grant

Similar Documents

Publication Publication Date Title
US6420013B1 (en) Multiply tissue paper
US5814188A (en) Soft tissue paper having a surface deposited substantive softening agent
US5389204A (en) Process for applying a thin film containing low levels of a functional-polysiloxane and a mineral oil to tissue paper
US5385643A (en) Process for applying a thin film containing low levels of a functional-polysiloxane and a nonfunctional-polysiloxane to tissue paper
US5059282A (en) Soft tissue paper
US20070144697A1 (en) Additive compositions for treating various base sheets
US5215626A (en) Process for applying a polysiloxane to tissue paper
US20080000602A1 (en) Wiping products having enhanced cleaning abilities
US20080073045A1 (en) Tissue products with controlled lint properties
US6887348B2 (en) Rolled single ply tissue product having high bulk, softness, and firmness
US20070295465A1 (en) Wiping products having enhanced cleaning abilities
US6245197B1 (en) Tissue paper products prepared with an ion-paired softener
US6579416B1 (en) Soft tissue paper having a softening composition containing an electrolyte deposited thereon
US5552020A (en) Tissue products containing softeners and silicone glycol
US6179961B1 (en) Tissue paper having a substantive anhydrous softening mixture deposited thereon
US20100239825A1 (en) Fibrous structure product with high softness
US6896766B2 (en) Paper wiping products treated with a hydrophobic additive
US5882743A (en) Absorbent folded hand towel
US20050252626A1 (en) Soft durable tissue
US20040084165A1 (en) Soft tissue products containing selectively treated fibers
US20080073046A1 (en) Process for increasing the basis weight of sheet materials
US7972475B2 (en) Soft tissue paper having a polyhydroxy compound and lotion applied onto a surface thereof
US20080041543A1 (en) Process for increasing the basis weight of sheet materials
US20090056892A1 (en) Multiple Ply Paper Product with Improved Ply Attachment and Environmental Sustainability
US6432270B1 (en) Soft absorbent tissue

Legal Events

Date Code Title Description
AS Assignment

Owner name: KIMBERLY-CLARK WORLDWIDE, INC., WISCONSIN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LIU, KOU-CHANG, MR.;REEL/FRAME:018509/0531

Effective date: 20061026